RT Journal Article SR Electronic T1 Metapneumovirus pneumonia in allogeneic stemcell transplant recipients JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP p2508 VO 38 IS Suppl 55 A1 Adrian Egli A1 Jörg Halter A1 Dominik Heim A1 Martin Stern A1 Christoph Bucher A1 Hans Hirsch A1 Michael Tamm YR 2011 UL http://erj.ersjournals.com/content/38/Suppl_55/p2508.abstract AB Infectious and noninfectious pulmonary complications are frequent in allogeneic stemcell transplant recipients (SCT) and associated with a high morbidity and mortality. Metapneumovirus (MPV) has recently been recognised to cause lethal infections in immunocompromised patients. Following an index case with fatal outcome we included PCR for Metapneumovirus in the routine work-up of BAL performed in hematological patients with pulmonary symptoms. We analysed the clinical presentation and outcome of 8 allogeneic stemcell transplant recipients with a median age of 45 year observed over a period of 12 months. Median Time to pulmonary MPV infection was 473 days after SCT. 6 of 8 patients were under immunosuppressive therapy for GvHD and 4 of them had biopsy proven bronchiolitis obliterans. All patients suffered from cough and 7/8 from fever. CT scan of the chest revealed a groundglas pattern in all but one cases. There were nodules in five cases and alveolar-interstitial infiltrates in also 5 cases. Enlarged lymphnodes were only present in one patient. In one patient there was concomitant infection with moraxella catharalis. Two patients showed viral double infection in the BAL (MPV/coronavirus; MPV/rhinovirus). All patients were hospitalizid because of marked symptoms or hypoxemia. Anemia was the most frequent sideeffect of antiviral treatment. 7 out of 8 patients recovered. The patient who died had developed MPV pneumonia within one month following SCT.Conclusion: Metapneumovirus pneumonia is not uncommon following allogeneic stemcell transplantation. Typical clinical features include fever, cough and a groundglas pattern on chest CT scan. Most patients recover under treatment with immunoglobulins and ribavarin.